title: [Successful treatment with oral low-dose sobuzoxane and etoposide combined with rituximab in an elderly patient with HHV-8-negative primary effusion lymphoma-like lymphoma].
abstract: Primary effusion lymphoma (PEL) is a rare B-cell lymphoma, characterized by human herpes virus 8 (HHV8) infection and serous effusions without detectable tumor masses. However, cases with HHV8 unrelated PEL have also been reported, mainly in Japan, and these are referred to as PEL-like lymphoma (PEL-LL). We describe a 70-year-old man with cardiac comorbidity who developed PEL-LL with pleural effusion. The patient achieved a complete response (CR) after treatment with oral low-dose sobuzoxane and etoposide combined with rituximab. To date, the patient has been in CR for about 7 months without chemotherapy. PEL-LL reportedly has a better prognosis than PEL. Because PEL-LL is positive for CD20, unlike PEL, combination therapy including rituximab may be effective. PEL-LL mainly affects elderly people, so that further investigation of tolerable and effective regimens is required.
authors.affiliation: Division of Hematology, National Kyushu Cancer Center, National Hospital Organization.
authors.forename: Kosuke
authors.initials: K
authors.lastname: Toyoda
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Abe
authors.forename: Mariko
authors.initials: M
authors.lastname: Tsuda
authors.forename: Shojiro
authors.initials: S
authors.lastname: Haji
authors.forename: Ilseung
authors.initials: I
authors.lastname: Choi
authors.forename: Youko
authors.initials: Y
authors.lastname: Suehiro
authors.forename: Junichi
authors.initials: J
authors.lastname: Kiyasu
authors.forename: Koichi
authors.initials: K
authors.lastname: Ohshima
authors.forename: Naokuni
authors.initials: N
authors.lastname: Uike
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D005047:Etoposide; D019288:Herpesvirus 8, Human; D006801:Humans; D008223:Lymphoma; D054685:Lymphoma, Primary Effusion; D008297:Male; D010879:Piperazines; D000069283:Rituximab
chemical_list: D010879:Piperazines; D000069283:Rituximab; D005047:Etoposide; C057773:sobuzoxane